Long-term safety of vedolizumab in patients with ulcerative colitis/Crohn's disease: A prospective observational study.

Date publication

octobre 2025

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Louis E, Sebastian S, Siegmund B, Bossuyt P, Danese S, de Boer N, Loftus EV, Moum B, Peyrin-Biroulet L, Schreiber S, Zhou J, Angellotti E, Adsul S, Jones S, Siegel CA

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41092971

Résumé

This post-authorization safety study compared long-term safety of vedolizumab or other biologics in patients with ulcerative colitis (UC) or Crohn's disease (CD).

Mots clés

Crohn’s disease, Safety, Ulcerative colitis, Vedolizumab

Référence

Clin Gastroenterol Hepatol. 2025 10 13;: